Announcing Sustainability Benchmarking Initiative and New Gen- AI Features of Pharma.AI Platform CAMBRIDGE, Mass. , July 24, 2024 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently hosts Insilico Medicine Generative AI Action (IMGAIA) webinar.
The webinar featured opening remarks by Alex Zhavoronkov , PhD, Founder and CEO of Insilico Medicine. During the virtual event, Alex Aliper, PhD, co-founder and president of Insilico Medicine, announced the company's sustainability initiative. Following this, the session on product launches and updates was delivered by key AI project leaders.
"Guided by the goal to accelerate scientific research and utilize the power of AI to the most, we announce the generative AI tools today," says Petrina Kamya , PhD, Global Head of Al Platforms and Vice President of Insilico Medicine . "These advancements not only underline our commitment to pioneering scientific breakthroughs but also reflect our dedication to achieving them responsibly, ensuring a healthier and more sustainable future." Focusing on the challenges posed by data limitations, complex biological processes and tedious document tasks, Insilico presents three novel applications under Pharma.
AI, the AI drug discovery platform, namely, Biology42: PandaOmics Box , Precious-3 GPT , and Science42: DORA . Biology42: PandaOmics Box , an industry-first AI-powered converged research solution currently co.